Settlement Docs Off-Limits In Rituxan Fraud Suit
A qui tam plaintiff accusing Genentech Inc. of defrauding Medicare through the promotion of off-label uses of its non-Hodgkin's lymphoma drug Rituxan has lost a bid to extract details of failed...To view the full article, register now.
Already a subscriber? Click here to view full article